Related Experiment Video

Updated: Nov 3, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.8K

CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma

Naoki Kawahara1, Yuki Yamada1, Hiroshi Kobayashi1

  • 1Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8521, Japan.

International Journal of Molecular Sciences
|June 2, 2021
PubMed
Abstract

Insights

Cyclin-E1 (CCNE1) is a novel synthetic lethal target for ARID1A-mutated ovarian clear cell carcinoma (OCCC). Targeting CCNE1 offers a potential new anticancer strategy for OCCC, which is resistant to current therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian clear cell carcinoma (OCCC) exhibits resistance to platinum chemotherapy, leading to poor patient prognosis.
  • Poly (ADP-ribose) polymerase (PARP) inhibitors are effective in platinum-sensitive ovarian cancer but show limited efficacy in OCCC.
  • The synthetic lethality approach offers targeted cancer treatment, but novel targets are needed for OCCC.

Purpose of the Study:

  • To identify novel synthetic lethal targets for ARID1A-mutated ovarian clear cell carcinoma (OCCC).
  • To investigate the role of Cyclin-E1 (CCNE1) as a potential therapeutic target in OCCC.

Main Methods:

  • Conducted siRNA screening to identify synthetic lethal partners for ARID1A mutations.
  • Utilized human OCCC cell lines (ARID1A mutant and wild-type) transfected with CCNE1-targeting siRNA.
  • Evaluated the impact of CCNE1 inhibition on cell viability and proliferation in vitro and in vivo using a xenograft mouse model.

Main Results:

  • Loss of CCNE1 significantly reduced proliferation in ARID1A-mutated OCCC cell lines (TOV-21G, KOC7c).
  • CCNE1 inhibition did not affect proliferation in ARID1A wild-type OCCC cell lines (RMG-I, ES2).
  • In vivo studies demonstrated that CCNE1 interference effectively inhibited tumor cell proliferation in a xenograft mouse model.

Conclusions:

  • CCNE1 is identified as a synthetic lethal target gene specifically in ARID1A-mutated OCCC.
  • Targeting CCNE1 presents a promising novel anticancer strategy for OCCC treatment.
  • This finding opens new avenues for molecular-targeted therapies in OCCC.
Keywords:
ARID1A mutationCyclin-E1ovarian clear cell carcinomasynthetic lethality

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.5K